SRDX SurModics
- 34.620
- +0.540+1.58%
- 34.620
- 0.0000.00%
SurModics News
Surmodics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Surmodics (SRDX) Q2 Earnings Top Estimates, '24 View Up
Surmodics Is Maintained at Outperform by Barrington Research
Surmodics Is Maintained at Outperform by Barrington Research
Barrington Research: Maintaining the Surmodics (SRDX.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $71.00 to $71.00.
Barrington Research: Maintaining the Surmodics (SRDX.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $71.00 to $71.00.
Barrington Ups Price Target on SurModics to $71 From $70, Maintains Outperform Rating
Barrington Ups Price Target on SurModics to $71 From $70, Maintains Outperform Rating.
Analysts Offer Insights on Healthcare Companies: CVS Health (CVS) and SurModics (SRDX)
The 28% Return This Week Takes Surmodics' (NASDAQ:SRDX) Shareholders One-year Gains to 45%
Passive investing in index funds can generate returns that roughly match the overall market. But if you pick the right individual stocks, you could make more than that. For example, the Surmodics, I
Earnings Call Summary | SurModics(SRDX.US) Q2 2024 Earnings Conference
The following is a summary of the Surmodics, Inc. (SRDX) Q2 2024 Earnings Call Transcript:Financial Performance:Surmodics reported Q2 revenue growth of 18% to $32 million, exceeding expectations.Medic
SurModics Up Nearly 31%, On Track for Largest Percent Increase Since July 2000 -- Data Talk
SurModics, Inc. ( SRDX ) is currently at $33.64, up $7.95 or 30.95% --Would be highest close since Feb. 12, 2024, when it closed at $34.08 --On pace for largest percent increase since July 6, 2000,
Surmodics Is Maintained at Buy by Needham
Surmodics Is Maintained at Buy by Needham
Surmodics Price Target Cut to $43.00/Share From $47.00 by Needham
Surmodics Price Target Cut to $43.00/Share From $47.00 by Needham
Needham: Maintaining the Surmodics (SRDX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $47.00 to $43.00.
Needham: Maintaining the Surmodics (SRDX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $47.00 to $43.00.
Needham Maintains Buy on Surmodics, Lowers Price Target to $43
Needham analyst Mike Matson maintains Surmodics (NASDAQ:SRDX) with a Buy and lowers the price target from $47 to $43.
Surmodics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/01/2024 27.98% Needham $47 → $43 Maintains Buy 04/10/2024 39.88% Needham → $47 Reiterates Buy → Buy 02/
SurModics Outperforms With Raised Guidance and Strong Product Momentum: Buy Rating Reaffirmed
Top Midday Gainers
Surmodics (SRDX) reported Wednesday a swing to earnings in fiscal Q2 as sales jumped more than forecast. Shares jumped 31% as intraday trading volume climbed to more than 127,000 versus the stock's da
Why AMD Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Advanced Micro Devices, Inc. (NASDAQ:AMD) fell sharply during Wednesday's session as the company reported first-quarter results and issued revenue guidance for the second quarter.AMD guided
SYT and STI Among Mid-day Movers
Surmodics Shares Are Trading Higher Following a Q2 Earnings Beat.
Surmodics Shares Are Trading Higher Following a Q2 Earnings Beat.
Powell Industries Posts Upbeat Results, Joins A10 Networks, Garmin, DuPont And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Dow Jones index gaining over 50 points on Wednesday.Shares of Powell Industries, Inc. (NASDAQ:POWL) rose sharply during Wednesday's session after the company reported
Analysis
Price Target
No Data
